Idioma:

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Golan, Talia ; Hammel, Pascal ; Reni, Michele ; Van Cutsem, Eric ; Macarulla, Teresa ; Hall, Michael J ; Park, Joon-Oh ; Hochhauser, Daniel ; Arnold, Dirk ; Oh, Do-Youn ; Reinacher-Schick, Anke ; Tortora, Giampaolo ; Algül, Hana ; O’Reilly, Eileen M ; McGuinness, David ; Cui, Karen Y ; Schlienger, Katia ; Locker, Gershon Y ; Kindler, Hedy L

The New England journal of medicine, 2019-07, Vol.381 (4), p.317-327 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Autor: Golan, Talia ; Hammel, Pascal ; Reni, Michele ; Van Cutsem, Eric ; Macarulla, Teresa ; Hall, Michael J ; Park, Joon-Oh ; Hochhauser, Daniel ; Arnold, Dirk ; Oh, Do-Youn ; Reinacher-Schick, Anke ; Tortora, Giampaolo ; Algül, Hana ; O’Reilly, Eileen M ; McGuinness, David ; Cui, Karen Y ; Schlienger, Katia ; Locker, Gershon Y ; Kindler, Hedy L
Assuntos: Adenocarcinoma - drug therapy ; Adenocarcinoma - genetics ; Adenocarcinoma - mortality ; Adenocarcinoma - secondary ; Adenosine ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Antitumor activity ; BRCA mutations ; BRCA1 protein ; BRCA2 protein ; Breast cancer ; Cancer therapies ; Chemotherapy ; Deoxyribonucleic acid ; DNA ; Double-Blind Method ; Drug therapy ; Female ; Genes, BRCA1 ; Genes, BRCA2 ; Genetic aspects ; Germ-Line Mutation ; Health risk assessment ; Humans ; Intervention ; Kaplan-Meier Estimate ; Maintenance Chemotherapy - adverse effects ; Male ; Medical imaging ; Metastases ; Metastasis ; Middle Aged ; Mutation ; Neoplasm Metastasis - drug therapy ; Ovarian cancer ; Pancreatic cancer ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - genetics ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - pathology ; Phthalazines - adverse effects ; Phthalazines - therapeutic use ; Piperazines - adverse effects ; Piperazines - therapeutic use ; Platinum ; Poly(ADP-ribose) polymerase ; Progression-Free Survival ; Quality of life ; Ribose ; Survival ; Tablets ; Tumors
É parte de: The New England journal of medicine, 2019-07, Vol.381 (4), p.317-327
Descrição: Approximately 7% of pancreatic cancers occur in patients with a germline mutation in BRCA1 or BRCA2 , an alteration that compromises DNA repair. In a randomized trial in patients with metastatic pancreatic cancer that had responded to platinum-based chemotherapy, progression-free survival was nearly twice as long with olaparib than with placebo (7.4 months vs. 3.8 months).
Editor: United States: Massachusetts Medical Society
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

United States: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.